Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Evelyn Walter

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
The Annals of Pharmacotherapy|April 29, 2004
Cost-effectiveness of escitalopram versus citalopram in the treatment of severe depressionMichiel E H Hemels, Siegfried Kasper, Evelyn Walter, et al.
Plos Neglected Tropical Diseases|July 11, 2017
Congenital toxoplasmosis in Austria: Prenatal screening for prevention is cost-savingAndrea-Romana Prusa, David C Kasper, Larry Sawers, et al.
The Pediatric Infectious Disease Journal|October 1, 2011
Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from AustriaBernhard Resch, Constanze Sommer, Mark J C Nuijten, et al.
Digital Health|February 6, 2025
Cost-effectiveness of the Floodlight<sup>®</sup> MS app in Austria. Unlocking the mystery of costs and outcomes of a digital health application for patients with multiple sclerosisEvelyn Walter, Matthäus Traunfellner, Franz Meyer, et al.
Journal of Medical Economics|January 3, 2012
Cost analysis: treatment of chemotherapy-induced anemia with erythropoiesis-stimulating agents in five European countriesAurea Duran, Erik Spaepen, Mark Lamotte, et al.
Journal of Medical Economics|February 13, 2020
Economic impact of industry-sponsored clinical trials of pharmaceutical products in AustriaEvelyn Walter, Gerald Eichhober, Marco Voit, et al.
Journal of Medical Economics|June 8, 2026
Tracking economic change over a decade: an analysis of Austria's industry-sponsored clinical trial landscape and implications for policyEvelyn Walter, Gerald Eichhober, Marco Voit, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
The Annals of Pharmacotherapy|April 29, 2004
Cost-effectiveness of escitalopram versus citalopram in the treatment of severe depressionMichiel E H Hemels, Siegfried Kasper, Evelyn Walter, et al.
Plos Neglected Tropical Diseases|July 11, 2017
Congenital toxoplasmosis in Austria: Prenatal screening for prevention is cost-savingAndrea-Romana Prusa, David C Kasper, Larry Sawers, et al.
The Pediatric Infectious Disease Journal|October 1, 2011
Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from AustriaBernhard Resch, Constanze Sommer, Mark J C Nuijten, et al.
Digital Health|February 6, 2025
Cost-effectiveness of the Floodlight<sup>®</sup> MS app in Austria. Unlocking the mystery of costs and outcomes of a digital health application for patients with multiple sclerosisEvelyn Walter, Matthäus Traunfellner, Franz Meyer, et al.
Journal of Medical Economics|January 3, 2012
Cost analysis: treatment of chemotherapy-induced anemia with erythropoiesis-stimulating agents in five European countriesAurea Duran, Erik Spaepen, Mark Lamotte, et al.
Journal of Medical Economics|February 13, 2020
Economic impact of industry-sponsored clinical trials of pharmaceutical products in AustriaEvelyn Walter, Gerald Eichhober, Marco Voit, et al.
Journal of Medical Economics|June 8, 2026
Tracking economic change over a decade: an analysis of Austria's industry-sponsored clinical trial landscape and implications for policyEvelyn Walter, Gerald Eichhober, Marco Voit, et al.
Pageof 3